- Business Wire•11 hours agoAlnylam Reports Positive Interim Phase 1 Results for Fitusiran in Hemophilia A and B Patients with Inhibitors
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced positive interim results from Part D of its ongoing Phase 1 study with fitusiran, an investigational RNAi therapeutic, in patients with hemophilia with inhibitors.
- Business Wire•11 hours agoAlnylam Reports Positive Initial Clinical Activity Results for Givosiran (ALN-AS1), an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced positive initial results from Cohorts 1 and 2 of Part C of its Phase 1 study with givosiran , the International Nonproprietary Name for ALN-AS1, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 for the treatment of acute hepatic porphyrias.
- Bloomberg•14 hours ago
Alnylam Pharmaceuticals Inc.’s experimental hemophilia drug helped control bleeding among hard-to-treat patients in an early-stage trial, suggesting it may compete with an expected blockbuster from Roche ...
ALNY : Summary for Alnylam Pharmaceuticals, Inc. - Yahoo Finance
Alnylam Pharmaceuticals, Inc. (ALNY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||40.30 x 100|
|Ask||47.50 x 100|
|Day's Range||40.62 - 42.82|
|52 Week Range||31.38 - 105.84|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-9.15|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|